Two senators from either side of the aisle introduced a bill this week that is aimed squarely at the patent strategies that are used to block biosimilars from coming to market.
Two senators from either side of the aisle introduced a bill this week that is aimed squarely at the patent strategies that are used to block biosimilars from coming to market.
Senator Susan Collins, R-Maine, and Senator Tim Kaine, D-Virginia, introduced the Biologic Patent Transparency Act, which would require companies to publicly disclose the patents that protect their originator biologics, thus making it easier for competitors to evaluate and plan for the development of biosimilars.
It is co-sponsored by Senators Rob Portman, R-Ohio; Jeanne Shaheen, D-New Hampshire; Mike Braun, R-Indiana; and Debbie Stabenow, D-Michigan.
If the transparency bill becomes law, it would codify the publication of FDA’s Purple Book as a single, searchable list, as well as require additional information:
In addition, it would limit the enforceability of late-filed patents by the biologic manufacturer when a biosimilar application has already been filed with the FDA, such as those used by AbbVie to protect its brand name adalimumab (Humira) from competition.
“The past century could be termed the Age of Miracle Drugs. Today, however, we might define a ‘miracle drug’ as one that has not doubled in price since the last refill,” Collins said in a statement. “We must provide drug makers with the ability to recoup their investments, but at the same time, we cannot be blind to the costs of these drugs, nor to cases where patent laws are manipulated to preserve monopolies. This legislation is an important step to stop the patent gaming that blocks consumers from accessing lower-cost biologics.”
“Biologic medicines can be life-changing for many patients, but we must do more to promote competition in the market to ensure patients can access and afford them. Our bill sheds light on the ways patents can be used to deter competition and encourages manufacturers to obtain key patents earlier, which will help bring new treatments to patients faster,” said Kaine.
Biologic manufacturers often seek to protect their products by using dozens or hundreds of patent thickets; even if some of the patents are later found to be invalid or unenforceable by the court or the Patent Trial and Appeal Board, expensive patent litigation can deter competitors from moving forward with developing biosimilars.
In an email to The Center for Biosimilars® , Michael A. Carrier, JD, distinguished professor at Rutgers Law School, noted that the issue of patent thickets, which keep generic and biologic competition out of the marketplace, has been receiving a lot of scrutiny in Congress, “so it’s possible this becomes law.”
For instance, in January, during a House Committee on Oversight and Reform hearing into drug prices, Aaron S. Kesselheim, MD, JD, MPH, of Harvard Medical School and Brigham and Women’s Hospital, testified that patent exclusivities constitute government-granted monopolies on drugs and pointed to the example of Humira’s “patent thicket” that has forestalled US competition until 2023.
“The restriction of enforcement of patents issued after a biosimilar has been submitted to FDA could encourage the earlier filing of patents and significantly open the thicket, facilitating biosimilars’ entry into the market,” wrote Carrier.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.